Price$14.85+5.63 (+60.98%)
2025-07-292025-10-29
Latest news
25 items- SECSEC Form EFFECT filed by 89bio Inc.EFFECT - 89bio, Inc. (0001785173) (Filer)
- SECSEC Form SCHEDULE 13G filed by 89bio Inc.SCHEDULE 13G - 89bio, Inc. (0001785173) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.SCHEDULE 13G/A - 89bio, Inc. (0001785173) (Subject)
- SECSEC Form 15-12G filed by 89bio Inc.15-12G - 89bio, Inc. (0001785173) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by 89bio Inc.SCHEDULE 13D/A - 89bio, Inc. (0001785173) (Subject)
- INSIDERDirector Ra Capital Management, L.P. returned 19,889,683 shares to the company (SEC Form 4)4 - 89bio, Inc. (0001785173) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by 89bio Inc.SCHEDULE 13D/A - 89bio, Inc. (0001785173) (Subject)
- INSIDERSEC Form 4 filed by Director Laporte Kathleen4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERDirector Hayden Michael R closing all direct ownership in the company (SEC Form 4)4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERChief Financial Officer Martins Ryan was granted 35,000 shares, closing all direct ownership in the company (SEC Form 4)4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERSEC Form 4 filed by Director Altschuler Steven4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERChief Executive Officer Palekar Rohan was granted 125,000 shares, closing all direct ownership in the company (SEC Form 4)4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERDirector Mcwherter Charles closing all direct ownership in the company (SEC Form 4)4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERSEC Form 4 filed by Director Atkinson Edward Morrow Iii4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERSEC Form 4 filed by Director Zoth Lota S.4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDEROfficer Le-Nguyen Quoc was granted 50,000 shares, closing all direct ownership in the company (SEC Form 4)4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERSEC Form 4 filed by Director Babler Martin4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERSEC Form 4 filed by Director Dirocco Derek4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERChief Operating Officer Sarena Francis Willard closing all direct ownership in the company (SEC Form 4)4 - 89bio, Inc. (0001785173) (Issuer)
- INSIDERChief Medical Officer Mansbach Harry H was granted 50,000 shares, closing all direct ownership in the company (SEC Form 4)4 - 89bio, Inc. (0001785173) (Issuer)
- SECSEC Form POSASR filed by 89bio Inc.POSASR - 89bio, Inc. (0001785173) (Filer)
- SECSEC Form POSASR filed by 89bio Inc.POSASR - 89bio, Inc. (0001785173) (Filer)
- SECSEC Form POS AM filed by 89bio Inc.POS AM - 89bio, Inc. (0001785173) (Filer)
- SECSEC Form S-8 POS filed by 89bio Inc.S-8 POS - 89bio, Inc. (0001785173) (Filer)
- SECSEC Form S-8 POS filed by 89bio Inc.S-8 POS - 89bio, Inc. (0001785173) (Filer)
ETNB FAQ
7 questionsWhat does 89bio Inc. do?
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.Where does ETNB stock trade?
89bio Inc. (ETNB) is listed on NASDAQ.What sector and industry is ETNB in?
89bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did 89bio Inc. go public?
89bio Inc. (ETNB) completed its IPO in 2019.What are analysts saying about ETNB?
89bio Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $3200.00 price target on 2025-09-04. Recent price targets range from $1100.00 to $3600.00.What companies are similar to ETNB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ETNB side-by-side with any of them on Quantisnow.How can I track ETNB on Quantisnow?
Quantisnow aggregates 89bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ETNB to receive live email and push alerts on every new disclosure.